PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-vaccinated and Breakthrough SARS-COV-2 Infected Cases
Shengule, S.; Alai, S.; Bhandare, S.; Patil, S.; Gautam, M.; Mangaonkar, B.; Gupta, S.; Shaligram, U.; Gairola, S. Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines2024, 12, 433.
Shengule, S.; Alai, S.; Bhandare, S.; Patil, S.; Gautam, M.; Mangaonkar, B.; Gupta, S.; Shaligram, U.; Gairola, S. Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines 2024, 12, 433.
Shengule, S.; Alai, S.; Bhandare, S.; Patil, S.; Gautam, M.; Mangaonkar, B.; Gupta, S.; Shaligram, U.; Gairola, S. Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines2024, 12, 433.
Shengule, S.; Alai, S.; Bhandare, S.; Patil, S.; Gautam, M.; Mangaonkar, B.; Gupta, S.; Shaligram, U.; Gairola, S. Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases. Vaccines 2024, 12, 433.
Abstract
Antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are multi-targeted and variable over time. Multiplex quantitative serological assays are needed to provide accurate and robust seropositivity data for establishment of serological signatures during vaccination and or infection. We describe here, validation and evaluation of an electro-chemiluminescence (ECL) based Mesoscale Discovery assays (MSD), for estimation of total and functional IgG to SARS-CoV-2 spike, nucleocapsid, and receptor binding (RBD) proteins in human serum samples to establish serological signatures of SARS-CoV-2 natural infection and breakthrough cases. The 9-PLEX assay was validated as per ICH, EMA and US FDA guidelines using a panel of sera samples including the NIBSC/WHO international reference panel (20/268). Assay demonstrated high specificity and selectivity in inhibition assays, wherein the homologous inhibition was more than 85% and heterologous inhibition was below 10 %. Assay also met predetermined acceptance criteria for precision (CV < 30 %), accuracy (70-130 %) and dilutional linearity. Method applicability to serological signatures was demonstrated using sera samples (N=45) representing vaccinated, infected and breakthrough cases. The method was able to establish distinct serological signatures and thus provide potential tool for seroprevalence of SARS-COV-2 during vaccination or infection.
Keywords
Coronavirus; variants of concerns; herd immunity; vaccine efficacy; Electrochemiluminescence
Subject
Biology and Life Sciences, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
